Skip to content

February 2026

Cannabis

What February 2026's 7 new studies found, synthesized from the papers below. All Cannabis research →

The synthesis

Synthesized from 3 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Cannabis, marijuana, THC, cannabidiol, CBD, then ranked by relevance.

Research on cannabis in February 2026 focused on its potential harms and correlates. Preclinical models show that cannabinoid exposure can alter schizophrenia-related behaviors, and gestational THC exposure in rats leads to distinct biomolecular changes in offspring brains. A large US survey found that lower perceived harm and higher mental health symptoms were associated with cannabis use and support for legalization. These findings are consistent in pointing to risks, but are limited by preclinical designs and cross-sectional survey data.

Confidence in the evidence

Low-Moderate
  • Only three studies directly address cannabis: one preclinical review, one animal study, and one cross-sectional survey.
  • The preclinical studies provide controlled evidence but are not directly translatable to humans.
  • The survey is large (n=3227) but cross-sectional, limiting causal inference.
  • Results are consistent in direction (cannabis associated with risks), but no clinical trials or meta-analyses are included.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Which Came First? Utility of Preclinical Models in Cracking the Chicken-or-Egg Relationship between Cannabis Use and Schizophrenia 2026
Supports

Preclinical rodent models show that cannabinoid exposure can alter schizophrenia-like behaviors and neural effects, with outcomes shaped by route, dose, and cannabinoid type.

review

Adult Rat Offspring Exposed to THC during Gestation Exhibit Distinct Biomolecular Changes Identified by X-ray Fluorescence Imaging and Fourier Transform Infrared Spectroscopy in Cortico-Limbic Circuits. 2026
Supports

Adult rat offspring exposed to THC during gestation exhibited decreased copper concentrations in the corpus callosum and changes in lipid structure and content in the hippocampus.

preclinical animal study

Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support 2026
Supports

Past-6-month cannabis use was associated with lower perceived addictiveness and harm, higher social acceptability, higher mental health symptoms, more adverse childhood experiences, and greater exposure to promotional and risk messages.

cross-sectional survey Sample size: 3227

Points of agreement

  • Cannabis exposure is associated with potential harms, including altered brain chemistry and behavior in animal models.
  • Lower perceived risk and higher mental health symptoms correlate with cannabis use in young adults.

Conflicts

No notable conflicts.

Gaps

  • No human clinical trials or longitudinal studies on cannabis effects are included.
  • Durability of effects and long-term outcomes are not addressed.
  • Dose-response relationships in humans are not examined.
  • The survey does not establish causality between cannabis use and mental health symptoms.
Browse these studies in the library